BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 28641631)

  • 21. Complex karyotype determined using conventional cytogenetic analysis is a poor prognostic factor in patients with multiple myeloma.
    Uryu H; Mishima Y; Ishihara Y; Shirouchi Y; Yamauchi N; Hirano M; Hirano K; Teramoto Y; Yoshida K; Maruyama D
    J Clin Exp Hematop; 2024; 64(1):10-20. PubMed ID: 38538316
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genomic aberrations in carcinomas of the uterine corpus.
    Micci F; Teixeira MR; Haugom L; Kristensen G; Abeler VM; Heim S
    Genes Chromosomes Cancer; 2004 Jul; 40(3):229-46. PubMed ID: 15139002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Cytogenetic characteristics of patients with multiple myeloma in China: analysis of 100 case].
    Deng SH; Xu Y; Wang YF; Mai YJ; Liu XP; Zhao YZ; Zou DH; Wang Y; Qiu LG
    Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(24):1685-8. PubMed ID: 17825148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.
    El-Galaly TC; Villa D; Alzahrani M; Hansen JW; Sehn LH; Wilson D; de Nully Brown P; Loft A; Iyer V; Johnsen HE; Savage KJ; Connors JM; Hutchings M
    Am J Hematol; 2015 Nov; 90(11):1041-6. PubMed ID: 26260224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study.
    Poirel HA; Cairo MS; Heerema NA; Swansbury J; Aupérin A; Launay E; Sanger WG; Talley P; Perkins SL; Raphaël M; McCarthy K; Sposto R; Gerrard M; Bernheim A; Patte C;
    Leukemia; 2009 Feb; 23(2):323-31. PubMed ID: 19020548
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome.
    Chigrinova E; Mian M; Scandurra M; Greiner TC; Chan WC; Vose JM; Inghirami G; Chiappella A; Baldini L; Ponzoni M; Ferreri AJ; Franceschetti S; Gaidano G; Tucci A; Facchetti F; Lazure T; Lambotte O; Montes-Moreno S; Piris MA; Nomdedeu JF; Uccella S; Rancoita PM; Kwee I; Zucca E; Bertoni F
    Hematol Oncol; 2011 Mar; 29(1):38-41. PubMed ID: 20635329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic impact of concordant and discordant bone marrow involvement and cell-of-origin in Korean patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Park MJ; Park SH; Park PW; Seo YH; Kim KH; Seo JY; Jeong JH; Kim MJ; Ahn JY; Hong J
    J Clin Pathol; 2015 Sep; 68(9):733-8. PubMed ID: 25998512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of trisomy 8 as a single anomaly and the influence of additional cytogenetic aberrations in primary myelodysplastic syndromes.
    Saumell S; Florensa L; Luño E; Sanzo C; Cañizo C; Hernández JM; Cervera J; Gallart MA; Carbonell F; Collado R; Arenillas L; Pedro C; Bargay J; Nomdedeu B; Xicoy B; Vallespí T; Raya JM; Belloch L; Sanz GF; Solé F
    Br J Haematol; 2012 Nov; 159(3):311-21. PubMed ID: 22958186
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities.
    Juliusson G; Oscier DG; Fitchett M; Ross FM; Stockdill G; Mackie MJ; Parker AC; Castoldi GL; Guneo A; Knuutila S; Elonen E; Gahrton G
    N Engl J Med; 1990 Sep; 323(11):720-4. PubMed ID: 2201915
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
    Ribera JM; Ortega JJ; Oriol A; Granada I; Hernández-Rivas JM; Parody R; Bethencourt C; Rivas C; Bastida P; del Potro E; González-Valentín ME; Moreno MJ; Besalduch J; Fernández-Calvo J; Tormo M; Arias J; Molinés A; Sanz MA; Maldonado J; Millá F; Feliu E; San Miguel JF;
    Haematologica; 2002 Feb; 87(2):154-66. PubMed ID: 11836166
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Karyotype and prognosis in non-Hodgkin lymphoma.
    Pirc-Danoewinata H; Chott A; Onderka E; Drach J; Schlögl E; Jäger U; Thalhammer F; Nowotny H; Aryee D; Steger GG
    Leukemia; 1994 Nov; 8(11):1929-39. PubMed ID: 7967739
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sites.
    Wang C; Li W; Liu C; He H; Bai O
    Blood Cells Mol Dis; 2016 Mar; 57():42-9. PubMed ID: 26852654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isolated bone marrow involvement in diffuse large B cell lymphoma: a report of three cases with review of morphological, immunophenotypic and cytogenetic findings.
    Alvares CL; Matutes E; Scully MA; Swansbury J; Min T; Gruszka-Westwood AM; Atkinson S; Hilditch B; Morilla R; Wotherspoon AC; Catovsky D
    Leuk Lymphoma; 2004 Apr; 45(4):769-75. PubMed ID: 15160954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytogenetic complexity and heterogeneity in intravascular lymphoma.
    Fujikura K; Yamashita D; Yoshida M; Ishikawa T; Itoh T; Imai Y
    J Clin Pathol; 2021 Apr; 74(4):244-250. PubMed ID: 32763919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical Characteristics and Correlation with Prognosis of DLBCL with Bone Marrow Involvement and Chromosomal Abnormalities].
    Li XL; Guan T; Zhao ZQ; Liu XL; Wang H; Su LP; Wang LY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Auguest; 31(5):1366-1371. PubMed ID: 37846686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recurrent Cytogenetic Abnormalities in Intravascular Large B-Cell Lymphoma.
    Klairmont MM; Cheng J; Martin MG; Gradowski JF
    Am J Clin Pathol; 2018 May; 150(1):18-26. PubMed ID: 29767679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytogenetic analysis of 363 consecutively ascertained diffuse large B-cell lymphomas.
    Cigudosa JC; Parsa NZ; Louie DC; Filippa DA; Jhanwar SC; Johansson B; Mitelman F; Chaganti RS
    Genes Chromosomes Cancer; 1999 Jun; 25(2):123-33. PubMed ID: 10337996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma.
    Obermann EC; Csato M; Dirnhofer S; Tzankov A
    J Clin Pathol; 2009 Oct; 62(10):903-7. PubMed ID: 19783718
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical characteristics and prognosis of primary Waldeyer's ring and lymph node diffuse large B-cell lymphoma in the rituximab era.
    Jing XM; Yu JR; Luo YK; Zhang SC; Liu JF; Li L; Wu P; Zhang ZH
    Leuk Res; 2017 Sep; 60():89-93. PubMed ID: 28772206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New chromosome abnormalities and lack of BCL-6 gene rearrangements in Argentinean diffuse large B-cell lymphomas.
    Cerretini R; Noriega MF; Narbaitz M; Slavutsky I
    Eur J Haematol; 2006 Apr; 76(4):284-93. PubMed ID: 16519699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.